Jacqueline Corrigan-Curay, the acting director of the Center for Drug Evaluation and Research wrote in an email to colleagues that she will be retiring from the agency in July.
Sen. Bill Cassidy (R-LA), a key Senate health leader, June 23 called for the meeting of the Advisory Committee on Immunization Practices to be delayed, citing concerns over the committee members’ lack of directly relevant experience and their potential bias against some vaccines.
In the fiscal year 2026 budget request, the Trump administration proposes “forward funding,” or multiyear funding, of awards.
A federal judge has called the Trump’s administration’s cancellation of NIH grants “illegal,” striking it down.
NIH Director Jay Bhattacharya has launched his own podcast called “The Director’s Desk,” where he plans to host weekly conversations on scientific careers, leadership, and innovation at NIH.
A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”
Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, who was named director of the FDA Center for Biologics Evaluation and Research in early May (The Cancer Letter, May 9, 2025), has now been also appointed chief medical and science officer at FDA, according to an internal memo obtained by The Cancer Letter.
FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.
NIH Director Jayanta Bhattacharya “prioritizes political momentum over human safety and faithful stewardship of public resources,” a group of Nobel laureates and over 300 NIH employees wrote in a letter.
In November 2024, Bobby Mukkamala was giving a routine talk to a group of physicians and medical students when his language suddenly became garbled. For a minute or two, he stopped making any sense.
